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28-CRP (DAS28-CRP)Abstract Background: Imbalanced Matrix Gla protein (MGP) and Osteoprotegerin (OPG) levels
occur in inﬂammatory diseases.
Aim of the work: The aim of the present study was to evaluate serum MGP and OPG levels in
Rheumatoid Arthritis (RA) patients and study their relation to the disease activity.
Patients and methods: Forty-ﬁve female RA patients and 45 age and sex-matched healthy con-
trols were included in this study. Disease activity score 28-C-reactive protein (DAS28-CRP) was
used for the assessment of disease activity. High-sensitivity C-reactive protein (hs-CRP), erythro-
cyte sedimentation rate (ESR), MGP and OPG were measured in patients and controls. The asso-
ciations of MGP and OPG with DAS28-CRP and the other laboratory and clinical variables were
analyzed.
112 A. Ghorbanihaghjo et al.Results: RA patients had signiﬁcantly higher serum OPG levels (408.3 ± 520.9 pg/ml) and hs-
CRP (2.8 ± 1.9 mg/l) than the control (92.5 ± 86.3 pg/ml and 0.9 ± 1.5 mg/l respectively)
(p< 0.001 each). There was no signiﬁcant difference in MGP levels between the patients and con-
trol (p= 0.3). The correlation of OPG and MGP with DAS28-CRP in the patients was insigniﬁcant
(p= 0.4 and p= 0.8 respectively). Age positively correlated with OPG (r= 0.32, p= 0.02), but
not with MGP concentration (r= 0.05, p= 0.64) in the RA patients.
Conclusions: The signiﬁcant elevation of the OPG level in RA patients may through light on its
possible role in the pathogenesis of this disease and could be considered as a future therapeutic
target. The signiﬁcant correlation with age suggests that OPG may be an important mediator
especially in elderly RA cases.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease with pol-
yarticular synovitis. It is characterized with the breakdown of
cartilage, juxta-articular bone, and generalized bone loss with
reduced bone mass. The consequences of this intense bone loss
are painful joint deformities, progressive functional disability,
and increased risk of bone fractures and increased mortality
rates [1].
Receptor activator of nuclear factor jB ligand (RANKL)
that belongs to the TNF superfamily, exists as a soluble form
(sRANKL) [2,3]. Receptor activator of nuclear factor jB li-
gand, expressed on osteoclasts/stromal lineage cells, plays a
stimulating role to transduce differentiation and send activa-
tion signals to osteoclast lineage cells through binding to its
receptor (RANK) which leads to osteoclastogenesis and bone
resorption in patients with RA [1,3]. Osteoprotegerin (OPG) is
produced by osteoblasts and it is an important regulator of
osteoclast development and function. Osteoprotegerin acts as
a decoy receptor by blocking RANKL–RANK binding pre-
venting osteoclastogenesis and bone resorption [4,5]. Its over-
expression acts as a consequence of inhibition of osteoclast
production and can cause osteoporosis in mice, while OPG
deletion leads to an increase in remodeling of bone and osteo-
porosis [6,7]. Thus, expression of RANKL and OPG give rise
to controlling RANK activation and balance between OPG
and RANKL levels; meanwhile, OPG plays fundamental roles
in order to determine the extent of bone resorption [8–10]. Pre-
vious studies reveal that disequilibrium of RANKL and OPG
together may indicate relatively skeletal complications as well
as deregulations of this system implicate the pathophysiology
of bone remodeling in patients with RA [11–13].
Several experiments clearly show the role of RANKL in
inﬂammatory joint disease in laboratory animal models. Acti-
vated T cells in vivo culminate in RANKL-mediated increase
in osteoclastogenesis and bone loss [14–16]. In RA, it has been
conﬁrmed that T-cell activation could cause osteoclastogenesis
within the synovium and this can be conducted via two mech-
anisms: (A) Secretion of RANKL by active T cells in inﬂamed
joints. (B) Increasing bone erosions. On the contrary, OPG
probably contributes to preventing inﬂammation-induced
bone resorption in RA patients [17]. Administration of OPG
to animals with arthritis blocks bone demolition; however,
with less inﬂuence on inﬂammation [18]. Serum OPG concen-
trations are also elevated in RA patients [19]. OPG is an effec-
tive inhibitor for differentiation of osteoclasts and couldprevent bone resorption in patients with RA [20]. Some evi-
dences suggest that the balance between OPG and RANKL
is important in prevention of joint destruction [21,22] and
therefore, data suggest that inhibition of RANKL function
via OPG plays a protective role to bone destruction in RA
patients [23].
Vascular calciﬁcation (VC) is known to be associated with a
high risk of coronary atherosclerosis morbidity and mortality
in RA patients [24]. Matrix Gla protein (MGP) is among the
most important inhibitors of VC [11,25]. Its effect on VC is
mediated by inhibiting of calcium crystal formation, with bind-
ing surplus calcium ions or small crystals in tissues and clear-
ing them from circulation [26,27]. Data demonstrate that
serum MGP concentrations in patients with calciﬁcation were
lower in comparison to patients without calciﬁcation [28,29].
Herrmann et al. [30] reported a signiﬁcant decrease in serum
MGP level with increased severity of coronary calciﬁcation.
Moe et al. [31] believe that OPG and MGP may protect against
VC in the uremic patients. Nevertheless studies including cor-
relations between serum OPG and MGP levels and disease
activity score including C-reactive protein (DAS28-CRP) in
patients with RA have not yet been reported.
The aim of the present study was to evaluate serum MGP
and OPG levels in female Rheumatoid Arthritis (RA) patients
and study their relation to the disease activity.2. Patients and methods
Forty-ﬁve women aged 46.5 ± 12.6 years affected by RA (Dis-
ease duration: 1–22 years) were compared with 45 healthy age,
sex and body mass index (BMI) matched controls
(43.2 ± 9.2 years). The median and range of the age was 48
(21–69) years in the RA group and 41(21–62) years in the
healthy control group (p= 0.2). Patients were selected consec-
utively from the Rheumatology Clinic of Tabriz University of
Medical Sciences (RCTUMS) between August 2010 and Jan
2011 and were enrolled into the study according to the
ACR/EULAR 2010 classiﬁcation criteria of RA [32]. Before
investigation, written informed consent was obtained from
all participants. Exclusion criteria in the present study
were patients with history of smoking or alcoholism, renal
disease, cardiovascular and liver inheritance systemic disease,
uncontrolled hypertension, nephrotic syndrome, diabetes mel-
litus, Cushing syndrome, thyroid disorders, anti-conception
drugs and metabolic diseases. The patients with changed drug
treatment schedule in the previous two months and during the
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patients were Prednisone (5–10 mg/day), Methotrexate (10–
25 mg/week), Sulfasalazine (1–3 g/day), Hydroxychloroquine
(200–400 mg/day), Cyclosporine (100–300 g/day), Azathioprine
(100–150 mg/day), non-steroidal anti-inﬂammatory drugs
(short-term interventions for control of Mechanical pains): Na-
proxen (250–500 mg/day), Ibuprofen (400–800 mg/day) and
Diclofenac (25–75 mg/day). The ethics committee of Tabriz
University of Medical Sciences reviewed and approved the study
which is in compliance with the Declaration of Helsinki.
2.1. Clinical assessments
The clinical examination was done by a rheumatologist and
DAS28-CRP was calculated according to the formula that is
composed of the number of tender and swollen joints, patient’s
global assessment of disease activity on a visual analogue scale
(VAS) and CRP. Erythrocyte sedimentation rate (ESR) tends
to reﬂect disease activity of the past few weeks, whereas
CRP reﬂects more short-term changes in disease activity.
Therefore, the advantage of CRP is that it is more sensitive
to short-term changes in disease activity. Furthermore, ESR
can be inﬂuenced by confounding factors such as age, sex,
ﬁbrinogen levels, hypergammaglobulinemia, rheumatoid fac-
tor and anemia. For these reasons, DAS28-CRP using CRP in-
stead of ESR was used in the present study [33].Table 1 Disease duration, factors of disease activity, anti-
cyclic citrullinated peptide (anti-CCP), complete blood count
(CBC) and medications received by the rheumatoid arthritis
patients.
Variables Rheumatoid arthritis
patients (N= 45)
Disease duration (years)a 4.5 (1–22)
Disease activity:
Swollen joint counta 2 (0–10)
Tender joint counta 2.8 (0–12)
ESR (mm/60 min)b 24.1 ± 14.3
DAS28-CRPb 2.5 ± 0.7
Anti-CCP (unit)a 149.5 (0.1–2290)
CBC:
WBC (mm3/l)a 7913.8 (3400–12,000)
Hemoglobin (g/dl)b 12.5 ± 1
Platelet (mm3/l)b 250346 ± 64,524
Medications: [n (%)]
Prednisone 42 (93.3)
Methotrexate 36 (80)
Sulfasalazine 8 (17.8)
Hydroxychloroquine 21 (46.7)
Cyclosporine 1 (2.20)
Azathioprine 3 (6.7)
NSAIDs 2 (4.4)
a Data are expressed as median (minimum–maximum).
b Values were expressed as the mean ± standard deviation (SD).
ESR: erythrocyte sedimentation rate, DAS28-CRP: disease
activity score-CRP, CRP: C-reactive protein, Anti-CCP: anti-
cyclic citrullinated peptide antibody, WBC: white blood cell,
NSAID: non-steroidal anti-inﬂammatory drug.2.2. Sample collection and analysis
All participants underwent blood sampling after 8 h fasting.
All samplings were performed in a period of 4 weeks. The sep-
arated serums were collected and stored in 70 C until labo-
ratory tests were done. The serum concentration of MGP was
measured by the Enzyme-Linked Immunosorbent Assay (ELI-
SA) employing commercial kits. (Uscn Life Science Inc,
Wuhan, China, Lot. No.:101018140, Detection range: 39–
2500 pg/ml, the sensitivity of the assay, or lower limit of detec-
tion was deﬁned as the lowest protein concentration that could
be differentiated from zero). The assay has high speciﬁcity for
detection of human MGP and no signiﬁcant cross-reactivity or
interference between human MGP and analogues was ob-
served. The serum concentration of OPG was measured by
ELISA employing commercial kits [Boster Immunoleader,
Wuhan, China, and Lot. No.:199656, Detection range: 93.8–
6000 pg/ml, sensitivity: >5 pg/ml. The assay has high speciﬁc-
ity for detection of human OPG and no detectible cross-
reactivity with any other cytokine was observed]. Anti-CCP
was measured by the Medizym anti-CCP Ref ELISA kit
(MEDIPAN GMBH, Ludwig-Erhard-Ring 3, 15827 Dahle-
witz/Berlin–Germany, the analytical sensitivity was established
to be 1.2 U/ml and the functional sensitivity was measured as
20% of inter-assay CV at about 2 U/ml). The concentration of
hs-CRP was determined by immunoturbidometry assay (Pars
Azmoon Co, Tehran, Iran). Serum creatinine (Cr), Alanine
aminotransferase (ALT), Aspartate aminotransferase (AST),
total cholesterol (TC), triglyceride (TG), total calcium and
phosphorus were measured by the enzymatic colorimetric
method (Pars Azmoon Co, Tehran, Iran) with an automated
chemical analyzer (Abbott analyzer, Abbott laboratories, Ab-
bott Park, North Chicago, IL). The ESR was measured using
whole blood and complete blood counts with differential countsanalyzed by the H1-Technicon blood cell counter. All case and
control samples were analyzed on the same day for each assay
kit.assay kit.
Statistical analysis: Statistical analyses were performed by
SPSS software version 18.0 (SPSS Ins, Chicago, IL). The Kol-
mogorov–Smirnov test was used to evaluate data distribution.
Results are expressed as median (minimum–maximum values),
or mean ± SD and Mann–Whitney U test or independent t-
test was used, as appropriate, to assess the signiﬁcance of
any differences between the two groups. All correlations were
evaluated using the Spearman test and the statistical signiﬁ-
cance was set at P< 0.05.
3. Results
Ninety subjects; composed of 45 patients with RA and 45
healthy controls, participated in this study. Disease duration,
components of disease activity, anti-cyclic citrullinated peptide
(anti-CCP), complete blood count (CBC) and medications
received by the rheumatoid arthritis patients are shown in
Table 1. Other demographic and laboratory features of the
patients and control are presented in Table 2.
Osteoprotegerin (OPG) did not correlated signiﬁcantly with
MGP in RA patients (r= 0.03, p= 0.86). Also, no signiﬁcant
correlations were found between the MGP and OPG with the
hs-CRP level in these patients (r= 0.24, p= 0.12; r= 0.18,
p= 0.23; respectively). Age positively correlated with OPG
Table 2 Demographic and laboratory characteristics of rheumatoid arthritis patients and controls.
Variables RA patients (n= 45) Controls (n= 45) p Value
Demographic features:
Age (years) 46.5 ± 12.6 43.2 ± 9.2 0.2
BMI (kg2/m) 29.7 ± 3.2 22.0 ± 2.7 0. 1
Diastolic BP (mmHg) 86 ± 9 74 ± 10 0.02
Systolic BP (mmHg) 146 ± 34 112 ± 9 0.04
Laboratory investigations:
ALT (Iu/l) 20.8 ± 10.3 10.6 ± 2.8 0.01
AST (Iu/l) 22.8 ± 9.3 11.0 ± 3.6 0.001
Creatinine (mg/dl) 0.9 ± 0.3 0.9 ± 0.2 0.7
Cholesterol (mg/dl) 217.6 ± 38.9 172.6 ± 13.9 0.002
Triglycerides (mg/dl) 142.7 ± 26.5 136.0 ± 32.2 0.6
Phosphorus (mg/dl) 4.2 ± 0.3 3.9 ± 0.3 0.001
Calcium (mg/dl) 9.5 ± 0.6 9.0 ± 0.5 0.002
OPG (pg/ml) 260.2 (18.8–3170) 69.4 (5.8–384) 0.001
(408.3 ± 520.9) (92.5 ± 86.3)
MGP (pg/ml) 20.6 (7.6–33) 18.0 (9.2–65.6) 0.3
(20.3 ± 5.5) (21.4 ± 10.9)
hs-CRP (mg/l) 2.6 (0.4–80) 0.3(0.1–6.6) 0.001
(2.8 ± 1.9) (0.9 ± 1.5)
Values are expressed as the mean ± standard deviation (SD) and values of the OPG, MGP and hs-CRP are also expressed as median (range).
BMI: body mass index, BP: blood pressure, ALT: alanine aminotransferase, AST: aspartic aminotransferase, OPG: osteoprotegerin, MGP:
Matrix Gla protein, hs-CRP: high-sensitivity C-reactive protein.
Figure 1 Correlation between osteoprotegerin (OPG) and age in
rheumatoid arthritis (RA) patients.
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(r= 0.05, p= 0.64) in the RA patients. No correlation was
found between, OPG and MGP levels and DAS28-CRP in
RA patients (p= 0.4 and p= 0.8 respectively).
4. Discussion
Rheumatoid Arthritis is among the most common inﬂamma-
tory joint disorders, which is associated with systemic inﬂam-
matory mediators [34]. Bone destruction is a main unsolved
problem in patients with RA. Published data have shown the
prevalent role of the OPG/RANK/RANKL triad in bone
pathophysiology. RANKL is the main osteoclast-stimulating
factor and many clinical studies indicated that increasedRANKL and/or decreased OPG, a soluble neutralizing recep-
tor for RANKL, could develop bone erosions. So, bone
resorption could be signiﬁcantly reduced by inhibition of
RANK as the receptor of RANKL and also by increasing
OPG level [35–37].
The results of the present study showed that RA patients
had signiﬁcantly higher serum OPG and hs-CRP concentra-
tions than healthy controls. Conﬂicting results have been sug-
gested about prevention or induction role of OPG for arterial
calciﬁcation [35–37]. Although OPG de novo could prevent
arterial calciﬁcation, its secretion secondarily to inﬂammatory
processes could mediate arterial calciﬁcation [38]. The mecha-
nism seems secondary to the expression and up regulation of
endothelial OPG, which is among the TNF alpha super family
[39]. Evidences also suggest the role of OPG as a proinﬂamma-
tory molecule and inducer of vascular calciﬁcation and athero-
sclerosis in RA [39–41].
In our study no signiﬁcant correlations between OPG,
MGP and hs-CRP were found in the RA patients, which does
not prove the results reported by Rhee et al. [42] who showed
an association of OPG with CRP and acute phase reactants.
The reason for this discrepancy may be due to different popu-
lation groups; the high CRP level in their study was in the pa-
tients with coronary artery disease. These patients had a
consistent situation without waxing and waning of inﬂamma-
tion, in contrast to our RA patients who did not have a con-
stant inﬂammation milieu. Survival of OPG would be
prolonged after binding to the Immunoglobulin-FC fragment
[43]. It may also occur in patients with RA. The ﬂuctuation
of CRP is not a reliable biomarker on one hand, and non-
decayed OPG on the other hand may be responsible for the
non-signiﬁcant correlation between hs-CRP and OPG [39].
Several investigators reported an excess of cardiovascular
morbidity and mortality in active RA and the majority of car-
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rosis. The presence and the extent of vascular calciﬁcations
are strong predictors for cardiovascular and all-causes of mor-
tality and morbidity in these patients [44–46]. Several factors
such as MGP, OPG, Osteopontin (OPN), and Fetuin-A may
act as inhibitor mediators for vascular calciﬁcation [47,48].
MGP is one major calciﬁcation inhibitor, released from hepa-
tocytes. It has been shown that lower serum MGP concentra-
tion is independently associated with the risk of cardiovascular
and all-cause mortality in patients, especially in renal failure
[49,50]. Cranenburg et al. [51] showed that MGP levels are
markedly lowered in hemodialysis patients and plasma MGP
correlated inversely with coronary artery calciﬁcation (CAC)
scores in these patients. In our study, we compared the
MGP levels in the RA and control subjects and no signiﬁcant
difference was found. Multiple unidentiﬁed factors such as ge-
netic polymorphism at the MGP locus may cause such disasso-
ciation [52] which should be considered in the future studies.
The correlation of OPG with age in RA patients, in con-
trast to the healthy controls, was observed in our study. Fras-
setto et al. [53] in their study have found this relationship also
in the healthy populations, which would be due to decreasing
GFR with aging. The age-related increase of OPG in our study
possibly represents a compensatory mechanism against age-
dependent bone loss or the effect of age on vascular calciﬁca-
tion in RA patients.
Some weaknesses of our study are lacking of the measure-
ment of the intima-media thickness (IMT), bone density and
radiological scores. Also, the possible effects of consumed
drugs in RA patients on OPG and MGP as well as hs-CRP lev-
els are major limitations of our study.
In conclusion, the signiﬁcant elevation of the OPG level in
RA patients may through light on its possible role in the path-
ogenesis of this disease and could be considered as a future
therapeutic target. The signiﬁcant correlation with age suggests
that OPG may be an important mediator especially in elderly
RA cases. The relationship of OPG and immunoglobulin-FC,
and other factors in RA needs further evaluation.Conﬂict of interest
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